Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

Collaboration builds on CAR-T commercialization in New Zealand and supports expansion across Australia, North America and other international markets.Wellington, New Zealand and Kingston, ...

As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is ...

Johnson & Johnson bets $1B on a Pennsylvania cell therapy plant as earnings momentum, pipeline deals, and MedTech approvals ...

CEO Brian Culley highlighted the progress of OpRegen, noting its differentiation from current anti-complement therapies for dry AMD. He emphasized, “OpRegen has shown evidence of both anatomical and ...

The regenerative medicine market is projected to reach $578 billion by 2033. Cell therapy alone surpassed $8.2 billion this year. And yet the central challenge of the entire sector remains unresolved: ...

Stem cell transplantation could be a rapid and effective way to restore hemoglobin production in individuals with the blood ...

Management continues to anticipate the presentation of three-year OpRegen trial data in June 2025, with Culley expressing hope it will “provide additional conviction in our approach.” There remains no ...